Document:

Exclusive License Agreement, dated January 6, 1995 - Endorecherche

 Exhibit 10.2 
 EXCLUSIVE LICENSE AGREEMENT 
 This EXCLUSIVE
LICENSE AGREEMENT is made and is effective this 6th day of January, 1995, by and between ENDORECHERCHE, having a principal place of business at 2989, De La
Promenade, Ste-Foy, Quebec G1W 2J5, Canada, hereinafter referred to as “LICENSOR”, and MYRIAD GENETICS, INC., having a principal place of business at 390 Wakara Way, Salt Lake City, Utah 84108, hereinafter referred to as
“LICENSEE”. 
 WITNESSETH: 
 WHEREAS, certain genetic research for the isolation, sequencing, and identification of cancer genes is being carried out by [***] and [***] at Endorecherche; 
 WHEREAS, LICENSEE has certain proprietary information and biological materials concerning the BRCA2 breast cancer gene; 
 WHEREAS, LICENSEE is desirous of collaborating with LICENSOR and obtaining exclusive rights from LICENSOR for the commercial development, use and sale of
any inventions that may result from the discovery of the BRCA2 breast cancer gene; 
 NOW THEREFORE, for and in consideration of the
covenants, conditions and undertakings hereinafter set forth, it is agreed by and between the parties, as follows: 
 1. DEFINITIONS 

 1.1. “LICENSED TECHNOLOGY”, as used herein, means technologies, trade secrets, know-how, information, technical data, or
materials, including but not limited to that which relates to research, development, nucleic acid constructions, genes, DNA fragments, gene sequences, bacterial or yeast strains, mammalian cell lines, biological material, chemical compounds,
proteins, products, formulas, substances, experimental plans, inventions, processes, formulations, techniques, methods, designs, data, drawing 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 
or other printed, written or electronically stored materials developed by [***] and [***] and their co-workers at Endorecherche, and which arose from the
research collaboration on the BRCA2 breast cancer gene. To the extent the BRCA2 breast cancer gene is isolated, characterized, developed or sequenced under this research collaboration, LICENSED TECHNOLOGY also includes: 
  

	 	(a)	the human BRCA2 gene(s); 

  

	 	(b)	any fragment(s) of material containing a DNA sequence from the BRCA2 gene(s); 

  

	 	(c)	any BRCA2 protein molecules; 

  

	 	(d)	nucleic acid molecules and monoclonal antibodies that bind to the BRCA2 gene(s) or its DNA sequence; 

  

	 	(e)	any mutations or altered form of the BRCA2 gene(s); 

  

	 	(f)	any animal or human homologues of the BRCA2 gene(s); 

  

	 	(g)	any other “technologies” and/or products developed under this research collaboration required for diagnostic or therapeutic commercial applications of the BRCA2 gene.

 LICENSED TECHNOLOGY further includes all uses of the BRCA2 gene(s) and its products, should they be isolated, characterized, developed or
sequenced under this research collaboration, including such uses as diagnostic and therapeutic applications. 
 1.2. “LICENSOR’S
PATENT RIGHTS”, as used herein, means patent rights to any subject matter claimed in or covered by any pending or issued U.S. and/or foreign patents and applications covering any aspects of LICENSED TECHNOLOGY; any new patents which may
hereinafter be filed covering aspects of LICENSED TECHNOLOGY; any continuing applications thereof; and any patents issuing on said applications or continuing applications including reissues. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 2 

 1.3. “LICENSED PRODUCTS”, as used herein, means any product, apparatus, kit or component part
thereof, or other subject matter (a) whose manufacture, use, or sale is covered by any claim or claims included within LICENSOR’S PATENT RIGHTS; [***] 
 1.4. “LICENSED METHODS”, as used herein, means any method, procedure, process or other subject matter (a) whose manufacture, use, or sale is covered by any claim or claims included within
LICENSOR’S PATENT RIGHTS; [***] 
 1.5. “...covered by...”, as used herein, means LICENSED PRODUCTS that when made, used, or
sold or LICENSED METHODS that when practiced would constitute, but for the license granted to LICENSEE pursuant to this Agreement, an infringement of any claim or claims of LICENSOR’S PATENT RIGHTS. 
 1.6. “NET SALES”, as used herein, means the gross income received by LICENSEE—either for (a) LICENSED PRODUCTS sold, or
(b) services performed using LICENSED PRODUCT or LICENSED METHOD—less the sum of the following deductions where applicable: case, trade or quantity discounts; sales, use, tariff, import/export duties or other excise taxes imposed upon
particular sales; transportation charges and allowances or credits to non-affiliated third parties because of rejections or returns; and uncollectible bad debts. 
 2. GRANT OF LICENSE 
 2.1. Except as otherwise provided herein, LICENSOR hereby grants to LICENSEE an
exclusive license under LICENSOR’S PATENT RIGHTS to make, have made, use, and sell LICENSED PRODUCTS and to practice the LICENSED METHODS throughout the world where LICENSOR may lawfully grant such a license. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 3 

 2.2. Additionally, except as provided herein, LICENSOR grants to LICENSEE an exclusive license to
practice [***] throughout the world where LICENSOR may lawfully grant such a license. 
 2.3. The license granted in Paragraph 2.1 and 2.2
above shall be exclusive from the effective date of this Agreement until the date of expiration of the last to expire of any patents included in LICENSOR’S PATENT RIGHTS. 
 2.4. LICENSOR retains the right to use LICENSED TECHNOLOGY for its own research and educational purposes. Once the BRCA2 gene has been isolated and
sequenced, LICENSEE shall make available to LICENSOR the DNA sequences, primers, cDNAs and other information concerning the BRCA2 breast cancer gene. 
 2.5. Nothing in this Agreement shall preclude LICENSOR from using publicly available information to perform future research in the BRCA2 or general cancer areas. 
 3. SUBLICENSES 
 3.1. LICENSOR also
grants to LICENSEE the right to issue sublicenses to third parties to make, have made, use and sell LICENSED PRODUCTS and to practice the LICENSED METHODS. These sublicenses shall include all of the rights and obligations due LICENSOR that are
contained in this Agreement to the extent applicable. LICENSEE shall pay LICENSOR the royalty rate on NET SALES by such Sublicensees at the same rate that would be due to LICENSOR from NET SALES by LICENSEE, although LICENSEE is free to charge
differential rates to Sublicensees. 
 3.2. LICENSEE shall provide LICENSOR with a copy of each sublicense issued hereunder; collect and
guarantee payment of all royalties due LICENSOR from sublicensees; and summarize and deliver all reports due LICENSOR from sublicensees. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 4 

 4. ROYALTIES 
 4.1. As consideration for this license, LICENSEE shall pay to LICENSOR an earned royalty rate on NET SALES based on the time of discovery of the BRCA2 gene as follows: 
  

				
	 Time of BRCA2 Discovery
	  	Royalty Rate	 
	 Discovery of BRCA2 gene within [***] of the date of this Agreement
	  	[***]	%
		
	 Discovery of BRCA2 gene after [***] but within [***] of the date of this Agreement
	  	[***]	%
		
	 Discovery of BRCA2 gene after [***] of the date of this Agreement
	  	[***]	%

 during any period where LICENSED PRODUCTS or LICENSED METHODS contain non-patentable proprietary LICENSED
TECHNOLOGY which is not otherwise available in the public domain or are covered by a pending or issued patent which has not been abandoned, withdrawn, denied, held invalid or unenforceable in a court of competent jurisdiction. LICENSED PRODUCTS
and/or LICENSED METHODS shall be considered sold when invoiced to a third party. All monies due to LICENSOR shall be payable in United States funds. 
 4.2. Royalties shall accrue in each country for the duration of LICENSOR’S PATENT RIGHTS in the country, or while non-patentable proprietary LICENSED TECHNOLOGY which is not otherwise available in the public
domain exists. 
 4.3. Royalties accruing to LICENSOR shall be paid to LICENSOR within [***] following the end of the calendar quarter in
which NET SALES are made. 
 4.4. In the event that any patent or any claim thereof included within the LICENSOR’S PATENT RIGHTS shall
be denied, withdrawn or held invalid in a decision by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based on such patent or claim or any claim patentably indistinct
therefrom shall cease as of the 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 5 

 
date of such decision. LICENSEE shall not, however, be relieved from paying any royalties that accrued before such decision or that are based on another
patent or claim not involved in such decision. 
 5. DUE DILIGENCE 
 5.1. LICENSEE, upon execution of this Agreement, shall [***] with the development, manufacture, sale and use of LICENSED PRODUCTS and/or LICENSED METHODS
and shall make them readily available to the general public. 
 5.2. LICENSEE shall be entitled to exercise prudent and justifiable business
judgment in meeting its due diligence obligations hereunder. The parties understand and agree that the due diligence obligations are subject to the LICENSEE’S [***] 
 6. QUARTERLY REPORTS 
 6.1. After the first occurrence of NET SALES, LICENSEE shall provide LICENSOR
with a written report showing all sales or use made of LICENSED PRODUCTS or LICENSED METHOD during the preceding calendar quarter. If no such sales or use has been made during any reporting period, a statement to this effect shall be required. These
reports shall be made no later than [***] following each calendar quarter. 
 6.2. LICENSEE agrees to report to LICENSOR the date of first
occurrence of NET SALES in each country within [***] of its occurrence. 
 7. BOOKS AND RECORDS 
 7.1. LICENSEE shall keep books and records accurately showing all LICENSED PRODUCTS manufactured, used, or sold under the terms of this Agreement. Such
books and records shall be open to inspection by representatives or agents of LICENSOR at reasonable times and after reasonable advance notice, for the purpose of verifying the accuracy of the quarterly reports and the royalties due or paid.

  
 Portions of this Exhibit were omitted and have been filed
separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 6 

 7.2. The fees and expenses of the representatives performing such an examination shall be borne by
LICENSOR. 
 7.3. These books and records required by Paragraph 8.1 herein shall be preserved for at least [***] from the date of the royalty
payment to which they pertain. 
 8. TERM OF RESEARCH COLLABORATION AND 
 LIFE OF THE AGREEMENT 
 8.1. The research collaboration between Endorecherche
and Myriad Genetics, Inc. can be terminated by either party after the BRCA2 breast cancer gene has been isolated and sequenced by giving the other party thirty (30) days advance written notice of their intent to terminate the research
collaboration. The termination of the research collaboration shall not affect the term of this Agreement or either party’s rights or obligations under this Agreement. 
 8.2. This Agreement shall be in full force and effect from the date first herein written and shall remain in effect for the life of the last-to-expire
patent licensed under this Agreement, or, in the case of non-patentable technology that is not available in the public domain, for fifteen (15) years, or unless otherwise terminated by operation of law or by acts of the parties in accordance
with the terms of Article 9 or Article 10 of this Agreement. 
 9. TERMINATION BY LICENSOR 
 9.1. It is expressly agreed that if LICENSEE should fail to deliver to LICENSOR any statement or report when due, or fail to make any payment, whether
fees or royalties, at the time that the same should be due, or if LICENSEE should violate or fail to perform any material covenant, condition, or undertaking of this Agreement on its part to be performed hereunder, then and in such 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 7 

 
event LICENSOR may give written notice of such default to LICENSEE. If LICENSEE should fail to repair such default within One Hundred Twenty (120) Days
of such notice or, in the alternative, to request Arbitration, LICENSOR shall have the right to terminate this Agreement and the license herein by written notice to LICENSEE. Upon such notice of termination, this Agreement shall automatically
terminate. Such termination shall not relieve LICENSEE of its obligation to pay any royalty or license fees due or owing at the time of such termination and shall not impair any accrued right of LICENSOR, including but not limited to the recovery of
any costs incurred in the enforcement of such accrued rights. LICENSEE shall pay all attorneys’ fees and court costs incurred by LICENSOR in enforcing any such obligation of LICENSEE or accrued right of LICENSOR after termination. 

10. TERMINATION BY LICENSEE 
 10.1.
LICENSEE shall have the right to terminate this Agreement or the license granted herein, in whole or as to any specified patent or claim of such patent, at any time and from time to time, by giving notice in writing to LICENSOR. Such termination
shall be effective Ninety (90) Days from such notice and all LICENSEE’S rights associated therewith shall cease as of that date. 
 10.2. Any termination pursuant to the above paragraph shall not relieve LICENSEE of any obligation or liability accrued hereunder prior to such termination, or rescind or give rise to any right to rescind anything done by LICENSEE or any
payments made or other consideration given to LICENSOR hereunder prior to the time such termination becomes effective, and such termination shall not affect in any manner any rights of LICENSOR arising under this Agreement prior to such termination.

  
 Portions of this Exhibit were omitted and have been filed
separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 8 

 11. PATENT PROSECUTION AND MAINTENANCE 
 11.1. LICENSEE shall [***] prosecute and maintain the United States and foreign patents and patent applications covering LICENSED TECHNOLOGY as it deems
appropriate, using counsel of its choice and after due consultation with LICENSOR. LICENSEE shall provide LICENSOR with copies of all relevant documentation so that LICENSOR may be informed and apprised of the continuing prosecution and LICENSOR
agrees to keep this documentation confidential. All patents will be assigned to the University of Utah. 
 11.2. LICENSEE agrees to pay all
costs and legal fees incurred for the prosecution, maintenance and taxes for patents covering LICENSED TECHNOLOGY and incurred after the effective date of this Agreement. 
 11.3. Any patent costs paid by LICENSEE pursuant to this Article shall be creditable toward royalty payments due to LICENSOR for NET SALES in the country where such patent costs were incurred. However, no credit may
be applied toward the minimum annual royalty payments and credits in any given reporting period may not be more than [***] of the royalty payment which otherwise would be due. Unused credit may be carried forward indefinitely until used. 

12. PATENT MARKING 
 12.1. LICENSEE
agrees to mark all LICENSED PRODUCTS made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. 
 13. WARRANTY BY LICENSOR 
 13.1. LICENSOR warrants that they have the lawful right to grant this
license. 
  
 Portions of this Exhibit were omitted and have been
filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 9 

 13.2. LICENSOR makes no express or implied warranties of merchantability or fitness of LICENSED
TECHNOLOGY for a particular purpose. 
 13.3. Nothing in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by LICENSOR as to the validity or scope of any LICENSOR’S PATENT RIGHTS; or 

  

	 	(b)	a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of
third parties; or 

  

	 	(c)	an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Article 14; or 

  

	 	(d)	conferring by implication, estoppel or otherwise any license or rights under any patents of LICENSOR other than LICENSOR’S PATENT RIGHTS as defined herein.

 14. INFRINGEMENT 
 14.1. In the event that LICENSEE shall learn of the infringement of any patent licensed under this Agreement, LICENSEE shall call LICENSOR’S attention thereto. LICENSEE shall use reasonable efforts to terminate such infringement. If
LICENSEE files a lawsuit for patent infringement, LICENSOR shall also be named as a plaintiff. In the event LICENSEE fails to abate the infringing activity within [***] LICENSOR may itself file a lawsuit for patent infringement, naming LICENSEE as
nominal party plaintiff. 
 14.2. Each party agrees to cooperate with the other in litigation proceedings instituted hereunder but at the
expense of the party on account of whom suit is brought. Such litigation shall be controlled by the party bringing the suit. LICENSOR at its own expense, may be represented by counsel of its choice pursuant to LICENSOR’S determination in any
suit brought by LICENSEE. 
  
 Portions of this Exhibit were omitted
and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 10 

 14.3. LICENSEE may withhold royalties payable to LICENSOR during the pendency of the suit and until said
suit has been finally concluded. To the extent that LICENSEE does not recover attorney’s fees and other out-of-pocket costs as a result of such litigation, such withheld royalties may be applied to LICENSEES expenses (out-of-pocket and
in-house) incurred in connection with such suit and the balance of such withheld royalties, if any, shall be paid to LICENSOR upon disposition of the suit; provided, however, that if as a result of such suit, all claims of patents included within
LICENSOR’S PATENT RIGHTS under which LICENSEE is selling a LICENSED PRODUCT shall be held invalid, LICENSEE may retain the balance of such withheld royalties which pertain to such LICENSED PRODUCT until such decision shall be finally reversed
by an unappealed or unappealable decree of a court of competent jurisdiction and of higher dignity. 
 15. WAIVER 
 15.1. It is agreed that no waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed
a waiver as to any subsequent and/or similar breach or default. 
 16. ASSIGNABILITY 
 16.1. This Agreement is binding upon and shall inure to the benefit of LICENSOR, its successors and assigns, but shall be personal to LICENSEE and
assignable by LICENSEE only with the written consent of LICENSOR, which consent shall not be unreasonably withheld; provided, however, that LICENSEE, without consent, may assign or sell the same in connection with the transfer or sale of all or
substantially all of its business relating to LICENSED PRODUCTS or LICENSED METHODS or in the event of merger or consolidation with another company. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 11 

 17. INDEMNITY 
 17.1. LICENSEE agrees to indemnify, hold harmless and defend LICENSOR, its officers, employees, and agents, against any and all claims, suits, losses, damage, costs, fees and expenses resulting from or arising out of
exercise of this license. 
 18. LATE PAYMENTS 
 18.1. In the event royalty payments or fees are not received by LICENSOR when due, LICENSEE shall pay to LICENSOR interest charges at the rate of [***] per annum on the total royalties or fees due for the reporting
period. 
 19. NOTICES 
 19.1. Any payment, notice or other communication required or permitted to be given to either party hereto shall be deemed to have been properly given and to be effective on the date of delivery if delivered in person or on the fourth day
after mailing if mailed by first-class certified mail, postage paid, to the respective address given below, or to such other address as it shall designate by written notice given to the other party as follows: 
 In the case of LICENSEE: 
 MYRIAD GENETICS,
INC. 
 390 Wakara Way 
 Salt Lake
City, Utah 84108 
 Attention: President 
 In the case of LICENSOR: 
 ENDORECHERCHE 
 2989, De La Promenade 
 Quebec G1W 2J5 
 Canada 
 Attention: [***] 
 Fax: (418) 651-1856 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 12 

 20. FOREIGN LAWS REGISTRATION 
 20.1. LICENSEE agrees to register this Agreement when required by local/national law, to pay all costs and legal fees connected therewith, and to
otherwise insure that the local/ national laws affecting this Agreement are fully satisfied. 
 20.2. LICENSEE agrees to abide by all U.S.
technology export regulations. 
 21. GOVERNING LAWS 
 21.1. This Agreement shall be interpreted and construed in accordance with the laws of the State of Utah. 
 22. MISCELLANEOUS 
 22.1. The headings of the several sections are inserted for convenience of reference only and are not
intended to be a part of or to affect the meaning or interpretation of this Agreement. 
 22.2. This Agreement will not be binding upon the
parties until it has been signed herein below by or on behalf of each party, in which event, it shall be effective as of the date first above written. 
 22.3. No amendment or modification hereof shall be valid or binding upon the parties unless made in writing and signed as aforesaid. 
 22.4. This Agreement embodies the entire understanding of the parties and shall supersede all previous communications, representations or understandings either oral or written between the parties relating to the
subject matter hereof. 
 22.5. In case any one or more of the provisions contained in this Agreement shall for any reason be held to be
invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions hereof, but this Agreement shall be construed as if such invalid or illegal or unenforceable provisions had never
been contained herein. 
  
 Portions of this Exhibit were omitted
and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 13 

 IN WITNESS WHEREOF, both LICENSOR and LICENSEE have executed this Agreement, in duplicate originals, by
their respective officers hereunto duly authorized, on the day and year hereinafter written. 
  

									
	MYRIAD GENETICS, INC.	 		 	ENDORECHERCHE
					
	By	 	 /s/ Peter D. Meldrum
	 		 	By	 	 /s/ Fernand Labrie

		 	(Signature)	 		 		 	(Signature)
	Name	 	Peter D. Meldrum	 		 	Name	 	Fernand Labrie
	Title	 	President and CEO	 		 	Title	 	President
					
	Date	 	January 6, 1995	 		 	Date	 	January 23, 1995

  
 Portions of this
Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 14Exclusive License Agreement, dated March 13, 1996 - Trustees of University of PA

 Exhibit 10.3 
 EXCLUSIVE LICENSE AGREEMENT 
 BETWEEN 
 MYRIAD GENETICS, INC. 
 AND 
 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934, as amended. 

 TABLE OF CONTENTS 
  

			
	 RECITALS
	  	1
		
	 ARTICLE 1 – DEFINITIONS
	  	1
		
	 ARTICLE 2 – LICENSE GRANT
	  	3
		
	 ARTICLE 3 – FEES AND ROYALTIES
	  	4
		
	 ARTICLE 4 – CONFIDENTIALITY
	  	6
		
	 ARTICLE 5 – TERM AND TERMINATION
	  	6
		
	 ARTICLE 6 – PATENT MAINTENANCE AND REIMBURSEMENT
	  	8
		
	 ARTICLE 7 – INFRINGEMENT AND LITIGATION
	  	8
		
	 ARTICLE 8 – DISCLAIMER OF WARRANTY; INDEMNIFICATION
	  	9
		
	 ARTICLE 9 – USE OF PENN’S NAME; INDEPENDENT CONTRACTOR
	  	11
		
	 ARTICLE 10 – ADDITIONAL PROVISIONS
	  	11

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the
Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

 This Exclusive License Agreement (“AGREEMENT”) is made by and between The Trustees of the
University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3700 Market Street, Suite 300, Philadelphia, Pennsylvania 19104-3147 (“PENN”) and Myriad Genetics, Inc., a corporation organized and existing under
the laws of Delaware (“MYRIAD”), having a place of business at 390 Wakara Way, Salt Lake City, UT 84108. 
 This AGREEMENT is
effective as of 3/13/1996 (“EFFECTIVE DATE”). 
 RECITALS 
 WHEREAS, PENN jointly owns and is a joint proprietor of certain intellectual property developed by [***] of PENN’s School of Medicine relating to the
human BRCA-2 breast cancer gene; and, 
 WHEREAS, PENN jointly owns, with Myriad and others, applications for United States letters patent
listed in Attachment 1 and attached hereto and foreign counterparts relating to the foregoing intellectual property developed by [***]; and, 
 WHEREAS, MYRIAD has participated in a collaborative research program with [***] relating to the human BRCA-2 breast cancer gene pursuant to the terms of a material transfer agreement dated as of 1/19/1995 (“MATERIAL TRANSFER
AGREEMENT”); and, 
 WHEREAS, MYRIAD desires to secure the exclusive right and license to use, develop, manufacture, have manufactured,
market, have marketed and exploit the intellectual property developed jointly by [***] and MYRIAD described in Attachment 1 hereto; and, 
 WHEREAS, PENN has determined that the exploitation of the intellectual property of [***] is in the best interest of PENN and is consistent with its educational and research missions and goals; and, 
 NOW, THEREFORE, in consideration of the premises and of the promises and covenants contained herein and intending to be legally bound hereby, the parties
agree as follows: 
 ARTICLE 1—DEFINITIONS 
 1.1 BANKRUPTCY EVENT means MYRIAD becomes insolvent, or voluntary or involuntary proceedings by or against MYRIAD are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for MYRIAD, or proceedings
are instituted by or against MYRIAD for corporate reorganization or the dissolution of MYRIAD, which proceedings, if voluntary, shall not have been dismissed within sixty (60) days after the date of filing, or MYRIAD makes an assignment for the
benefit of creditors, or substantially all of the assets of MYRIAD are seized or attached and not released within sixty (60) days thereafter. 
 1.2 CALENDAR QUARTER means each three-month period, or any portion thereof, beginning on January 1, April 1, July 1 and October 1. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s
application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 1 

 1.3 CALENDAR YEAR means a period of twelve (12) months beginning on January 1 and ending on
December 31. 
 1.4 CONFIDENTIAL INFORMATION means and includes all technical information, inventions, developments, discoveries,
software, know-how, methods, techniques, formulae, data, processes and other proprietary ideas, whether or not patentable or copyrightable, that PENN identifies as confidential or proprietary at the time it is delivered or communicated to MYRIAD.

 1.5 FAIR MARKET VALUE means the cash consideration which MYRIAD or its sublicensee would realize from an unaffiliated, unrelated buyer in
an arm’s length sale of an identical item sold in the same quantity and at the same time and place of the transaction. 
 1.6 FEDERAL
GOVERNMENT INTEREST means the rights of the United States Government under Public Laws 96-517, 97-256 and 98-620, codified at 35 U.S.C. 200-212, and any regulations issued thereunder, as statute or regulations may be amended from time to time
hereafter. 
 1.7 FIELD OF USE means any and all applications and uses of the BRCA-2 breast cancer gene, including but not limited to all
diagnostic and therapeutic applications. 
 1.8 JOINT LICENSED PRODUCT(S) means products which in the absence of this AGREEMENT would
infringe at least one claim of JOINT PATENT RIGHTS or products which are made using a process or machine covered by a claim of JOINT PATENT RIGHTS. 
 1.9 JOINT PATENT RIGHTS means those United States patent applications and foreign counterparts including continuation, divisional and re-issue applications thereof and continuation-in-part applications thereof based upon intellectual
property discovered by PENN through [***] jointly with one or more inventors of MYRIAD, as a result of the collaborative research between the parties, together with any and all patents issuing thereupon. 
 1.10 NET SALES means the gross sales amounts or, if such consideration does not exist, FAIR MARKET VALUE received by MYRIAD or its sublicensee from the
SALE of any JOINT LICENSED PRODUCT(S), in each case, in finished package form suitable for distribution to physicians, pharmacies, hospitals or other final users, less qualifying costs directly attributable to such SALE borne by MYRIAD or its
sublicensee. 
 1.10.1 Such qualifying costs shall be limited to the following: 
 1.10.1.1 Discounts, in amounts customary in the trade, for quantity purchases, prompt payments and for wholesalers and distributors. 
 1.10.1.2 Credits or refunds, not exceeding the original invoice amount, for claims or returns. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 2 

 1.10.1.3 Prepaid outbound transportation expenses and transportation insurance premiums. 
 1.10.1.4 Sales excise and use taxes, tariff, import/export duties and other fees imposed by a governmental agency. 
 1.11 SALE means any bona fide transaction for which consideration is received or expected for the sale, use, lease, transfer or other disposition of
JOINT LICENSED PRODUCTS. A SALE of JOINT LICENSED PRODUCTS shall be deemed completed at the time MYRIAD or its sublicensee invoices, ships, or receives payment for such JOINT LICENSED PRODUCTS, whichever occurs first. 
 ARTICLE 2—LICENSE GRANT 
 2.1 PENN grants to
MYRIAD for the term of this AGREEMENT an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use and sell JOINT LICENSED PRODUCTS. No other rights or licenses are granted hereunder. 
 2.2 The license grant of this Article 2 is exclusive but for the reserved right of PENN to use and permit other nonprofit organizations to use the JOINT
PATENT RIGHTS, under a written agreement protecting the commercial rights of MYRIAD, for educational and research purposes. 
 2.3 MYRIAD
acknowledges that in accordance with the FEDERAL GOVERNMENT INTEREST, the United States government retains certain rights in intellectual property funded in whole or part under any contract, grant or similar agreement with a Federal agency,
including but not limited to the requirement that JOINT LICENSED PRODUCTS subject to SALE in the United States must be substantially manufactured in the United States. The license grant of this Article 2 is expressly subject to all of such rights.

 2.4 The right to sublicense conferred upon MYRIAD under this AGREEMENT is subject to the following conditions: 
 2.4.1 In each such sublicense, the sublicensee shall be prohibited from further sublicensing without express written permission from PENN which shall not
be unreasonably withheld, and shall be subject to the terms and conditions of the license granted to MYRIAD under this AGREEMENT. 
 2.4.2
MYRIAD shall forward to PENN, within thirty (30) days of execution, a complete and accurate copy written in the English language of each sublicense granted hereunder. PENN’ S receipt of such sublicense shall not constitute an approval of
such sublicense or a waiver of any of PENN’s rights or MYRIAD’s obligations hereunder. 
 2.4.3 If MYRIAD becomes subject to a
BANKRUPTCY EVENT, all payments then or thereafter due and owing to MYRIAD from its sublicensees shall upon notice from PENN to any such sublicensee become payable directly to PENN for the account of MYRIAD; provided however, that PENN shall remit to
MYRIAD the amount by which such payments exceed the amounts owed by MYRIAD to PENN. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 
  

 3 

 2.4.4 Notwithstanding any such sublicense, MYRIAD shall remain primarily liable to PENN for all of
MYRIAD’S duties and obligations ,contained in this AGREEMENT, and any act or omission of a sublicensee which would be a breach of this AGREEMENT if performed by MYRIAD shall be deemed to be a breach by MYRIAD of this AGREEMENT. 
 ARTICLE 3—ROYALTIES 
 3.1 ROYALTIES 

3.1.1 In consideration of the exclusive license granted herein, MYRIAD shall pay to PENN a royalty of [***] of the NET SALES of JOINT LICENSED PRODUCTS
made, made for, used or sold by MYRIAD and any sublicensees. 
 3.1.2 In the event that a JOINT LICENSED PRODUCT is sold in the form of a
combination product containing one or more active ingredients (such as the BRCA-1 gene) which are themselves not JOINT LICENSED PRODUCTS, the NET SALES shall be calculated by multiplying the sales price of such combination product by the fraction
A/(A+B) where A is the invoice price or FAIR MARKET VALUE of the JOINT LICENSED PRODUCT and B is the total invoice price or FAIR MARKET VALUE of the other active ingredients. In the case of a combination product which includes one or more JOINT
LICENSED PRODUCTS, the NET SALES upon which the royalty due PENN is based shall not be less than the normal aggregate NET SALES for such JOINT LICENSED PRODUCTS. 
 3.2 MILESTONES 
 3.2.1 MYRIAD shall use its [***] to develop for commercial use and to market JOINT LICENSED
PRODUCTS [***]. 
 3.2.2 MYRIAD shall provide PENN on each [***] with written reports, setting forth in such detail as PENN may reasonably
request, the progress of the development, evaluation, testing and commercialization of the JOINT LICENSED PRODUCTS. MYRIAD shall also notify PENN within [***] of any JOINT LICENSED PRODUCT. 
 3.3 REPORTS AND RECORDS 
 3.3.1 MYRIAD shall
deliver to PENN within [***] after the end of each CALENDAR QUARTER a report, certified by the chief financial officer of MYRIAD setting forth in reasonable detail the calculation of the royalties due to PENN for such CALENDAR QUARTER, including,
without limitation: 
 3.3.1.1 Number of JOINT LICENSED PRODUCTS involved in SALES, listed by country. 
  
 Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 4 

 3.3.1.2 Gross consideration for SALES of JOINT LICENSED PRODUCTS, including all amounts invoiced,
billed, or received. 
 3.3.1.3 Qualifying costs, as defined in Section 1.10, listed by category of cost. 
 3.3.1.4 NET SALES of JOINT LICENSED PRODUCTS listed by country. 
 3.3.1.5 Royalties owed to PENN, listed by category, including without limitation earned and sublicensee-derived categories. 
 3.3.2 Royalties payable under Section 3.1 hereof shall be paid within [***] following the last day of the CALENDAR QUARTER in which the royalties accrue and shall accompany the report of Section 3.3.1.

 3.3.3 MYRIAD will maintain and cause its sublicensees to maintain, complete and accurate books and records which enable the royalties
payable hereunder to be verified. The records for each CALENDAR QUARTER shall be maintained for [***] after the submission of each report under Article 3 hereof. Upon reasonable prior notice to MYRIAD, PENN and its accountants shall have access to
all books and records relating to the SALES of JOINT LICENSED PRODUCTS by MYRIAD and its sublicensees to conduct a review or audit thereof. Such access shall be available not more than once each CALENDAR YEAR, during normal business hours, and for
each of three years after the expiration or termination of this AGREEMENT. If PENN determines that MYRIAD has underpaid royalties by [***] or more, MYRIAD will pay the costs and expenses of PENN and its accountants in connection with their review or
audit. 
 3.4 CURRENCY, PLACE OF PAYMENT, INTEREST 
 3.4.1 All dollar amounts referred to in this AGREEMENT are expressed in United States dollars. All payments to PENN under this AGREEMENT shall be made in United States dollars by check payable to “The Trustees of
the University of Pennsylvania.” 
 3.4.2 If MYRIAD receives revenues from SALES of JOINT LICENSED PRODUCTS in currency other than
United States dollars, revenues shall be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of The Wall Street Journal as of the last business day of the applicable
CALENDAR QUARTER. 
 3.4.3 Amounts that are not paid when due shall accrue interest from the due date until paid, at a rate equal to [***]
per month (or the maximum allowed by law, if less). 
  
 Portions of
this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

  

 5 

 ARTICLE 4—CONFIDENTIALITY 
 4.1 CONFIDENTIALITY 
 4.1.1 MYRIAD agrees to maintain in confidence and not to disclose to any third party
any CONFIDENTIAL INFORMATION of PENN received pursuant to this AGREEMENT. MYRIAD agrees to ensure that its employees have access to CONFIDENTIAL INFORMATION only on a need-to-know basis and are obligated in writing to abide by MYRIAD’s
obligations hereunder. The foregoing obligation shall not apply to: 
 4.1.1.1 information that is known to MYRIAD or independently developed
by MYRIAD prior to the time of disclosure, in each case, to the extent evidenced by written records promptly disclosed to PENN upon receipt of the CONFIDENTIAL INFORMATION; 
 4.1.1.2 information disclosed to MYRIAD by a third party that has a right to make such disclosure; 
 4.1.1.3 information that becomes patented, published or otherwise part of the public domain as a result of acts by PENN or a third person obtaining such
information as a matter of right; or 
 4.1.1.4 information that is required to be disclosed by order of United States governmental authority
or a court of competent jurisdiction; provided that MYRIAD shall use its best efforts to obtain confidential treatment of such information by the agency or court. 
 4.2 PENN shall not be obligated to accept any confidential information from MYRIAD. PENN bears no institutional responsibility for maintaining the confidentiality of any confidential information of MYRIAD. 

4.3 The placement of a copyright notice on any CONFIDENTIAL INFORMATION shall not be construed to mean that such information has been published and
will not release MYRIAD from its obligation of confidence hereunder. 
 ARTICLE 5—TERM AND TERMINATION 
 5.1 This AGREEMENT, unless sooner terminated as provided herein, shall terminate upon the expiration of the last to expire or become abandoned of the
JOINT PATENT RIGHTS. 
 5.2 MYRIAD may, at its option, terminate this AGREEMENT at any time by doing all of the following: 
 5.2.1 By ceasing to make, have made, use and sell all JOINT LICENSED PRODUCTS; and 
 5.2.2 By terminating all sublicenses, and causing all sublicensees to cease making, having made, using and selling all JOINT LICENSED PRODUCTS; and

  
 Portions of this Exhibit were omitted and have been filed
separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 6 

 5.2.3 By giving sixty (60) days notice to PENN of such cessation and of MYRIAD’s intent to
terminate; and 
 5.2.4 By tendering payment of all accrued royalties. 
 5.3 PENN may terminate this AGREEMENT if any of the following occur: 
 5.3.1 MYRIAD becomes more than sixty (60) days in arrears in payment of royalties or expenses due pursuant to this AGREEMENT and MYRIAD does not provide full payment immediately upon demand; or 
 5.3.2 MYRIAD becomes subject to a BANKRUPTCY EVENT; or 
 5.3.3 MYRIAD breaches this AGREEMENT and does not cure such breach within sixty (60) days written notice thereof. 
 5.4 PENN may also terminate this AGREEMENT if: 
 5.4.1 five years have elapsed from the EFFECTIVE DATE of
this AGREEMENT; and 
 5.4.2 MYRIAD has not submitted a JOINT LICENSED PRODUCT for FDA, or its foreign equivalent, regulatory approval; or

 5.4.3 MYRIAD has not made a SALE of a JOINT LICENSED PRODUCT or has no sublicensees doing so; or 
 5.4.4 MYRIAD has not met milestones specified in Section 3.2; and 
 5.4.5 PENN has given MYRIAD sixty (60) days notice of intent to terminate. 
 5.5 If MYRIAD becomes
subject to a BANKRUPTCY EVENT, all duties of PENN and all rights (but not duties) of MYRIAD under this AGREEMENT shall immediately terminate without the necessity of any action being taken either by PENN or by MYRIAD. To secure the complete and
timely payment and satisfaction of all MYRIAD’s royalty obligations under this AGREEMENT, MYRIAD hereby grants to PENN a security interest, effective immediately, in MYRIAD’s entire right, title and interest in and to this AGREEMENT and to
all inventories of JOINT LICENSED PRODUCTS now or hereafter owned by MYRIAD. In addition to any rights or remedies provided for under this AGREEMENT, PENN shall have all of the rights and remedies of a secured party under the Uniform Commercial
Code. Upon the request and at the sole expense of PENN, MYRIAD shall execute any and all instruments or documents as shall be reasonably necessary to evidence and perfect such security interest in any jurisdiction. 
 5.6 Upon termination of this AGREEMENT, MYRIAD shall, at PENN’ s request, return to PENN all CONFIDENTIAL INFORMATION fixed in any tangible medium
of expression as well as any data generated by MYRIAD during the term of this AGREEMENT which will facilitate the development of the technology licensed hereunder. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 7 

 5.7 MYRIAD’s obligation to pay royalties accrued under Article 3 hereof shall survive termination of
this AGREEMENT. In addition, the provisions of Articles 4, 5, 8, 9 and 10 shall survive such termination. 
 ARTICLE 6—PATENT MAINTENANCE AND
REIMBURSEMENT 
 6.1 MYRIAD shall [***] prosecute and maintain JOINT PATENT RIGHTS at its sole expense and shall promptly reimburse PENN
for all expenses and other charges incident to the preparation of JOINT PATENT RIGHTS. PENN shall provide MYRIAD with itemized statements reflecting these expenses and MYRIAD shall reimburse PENN for such expenses within [***] after receipt of such
statement. 
 6.2 MYRIAD and its sublicensees shall comply with all United States and foreign laws with respect to patent marking of JOINT
LICENSED PRODUCTS. 
 ARTICLE 7—INFRINGEMENT AND LITIGATION 
 7.1 PENN and MYRIAD are responsible for notifying each other promptly of any infringement of JOINT PATENT RIGHTS which may come to their attention, including notice to the other of any certification filed under the
United States “Drug Price Competition and Patent Term Restoration Act of 1984”. PENN and MYRIAD shall consult one another in a timely manner concerning any appropriate response thereto. 
 7.2 MYRIAD shall have the right, but not the obligation to prosecute such infringement at its own expense. MYRIAD shall not settle or compromise any such
suit in a manner that imposes any obligations or restrictions on PENN or grants any rights to the JOINT PATENT RIGHTS, without PENN’S written permission. Financial recoveries from any such litigation will first be applied to reimburse MYRIAD
for its litigation expenditures with additional recoveries being paid to MYRIAD, subject to a royalty due PENN based on the provisions of Article 3 hereof. 
 7.3 If MYRIAD fails to prosecute such infringement, PENN shall have the right, but not the obligation, to prosecute such infringement at its own expense. In such event, financial recoveries will be entirely retained
by PENN. 
 7.4 In any action to enforce any of the JOINT PATENT RIGHTS, either party, at the request and expense of the other party shall
cooperate to the fullest extent reasonably possible. This provision shall not be construed to require either party to undertake any activities, including legal discovery, at the request of any third party except as may be required by lawful process
of a court of competent jurisdiction. 
  
 Portions of this Exhibit
were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 8 

 ARTICLE 8—DISCLAIMER OF WARRANTY; INDEMNIFICATION 
 8.1 THE JOINT PATENT RIGHTS, JOINT LICENSED PRODUCTS AND ALL OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS AND
PENN MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY WAY OF EXAMPLE BUT NOT OF LIMITATION, PENN MAKES NO REPRESENTATIONS OR WARRANTIES (i) OF COMMERCIAL UTILITY; (ii) OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE; OR (iii) THAT THE USE OF THE JOINT PATENT RIGHTS, JOINT LICENSED PRODUCTS AND ALL TECHNOLOGY LICENSED UNDER THIS AGREEMENT WILL NOT INFRINGE ANY PATENT, COPYRIGHT OR TRADEMARK OR OTHER PROPRIETARY OR PROPERTY RIGHTS OF
OTHERS_ PENN SHALL NOT BE LIABLE TO MYRIAD, MYRIAD’S SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO: ANY CLAIM ARISING FROM THE USE OF THE JOINT PATENT RIGHTS, JOINT LICENSED PRODUCTS AND ALL TECHNOLOGY LICENSED UNDER THIS AGREEMENT
OR FROM THE MANUFACTURE, USE OR SALE OF JOINT LICENSED PRODUCTS; OR ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND. 
 8.2 MYRIAD will defend, indemnify and hold harmless PENN, its trustees, officers, agents and employees (individually, an “Indemnified Party”,
and collectively, the “Indemnified Parties”), from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by the Indemnified Parties (including attorney’s fees) (individually, a
“Liability”, and collectively, the “Liabilities”) that results from or arises out of: (a) the development, use, manufacture, promotion, sale or other disposition, of any JOINT PATENT RIGHTS or JOINT LICENSED PRODUCTS by
MYRIAD, its assignees, sublicensees, vendors or other third parties; (b) breach by MYRIAD of any covenant or agreement contained in this AGREEMENT; and (c) the enforcement by an Indemnified Party of its rights under this Section. Without
limiting the foregoing, MYRIAD will defend, indemnify and hold harmless the Indemnified Parties from and against any Liabilities resulting from: 
 8.2.1 any product liability or other claim of any kind related to the use by a third party of a JOINT LICENSED PRODUCT that was manufactured, sold or otherwise disposed by MYRIAD, its assignees, sublicensees, vendors or other third parties;

 8.2.2 a claim by a third party that the JOINT PATENT RIGHTS or the design, composition, manufacture, use, sale or other disposition of any
JOINT LICENSED PRODUCT infringes or violates any patent, copyright, trademark or other intellectual property rights of such third party; and 
 8.2.3 clinical trials or studies conducted by or on behalf of MYRIAD relating to the JOINT PATENT RIGHTS or JOINT LICENSED PRODUCTS, including, without limitation, any claim by or on behalf of a human subject of any such clinical trial or
study, any claim arising from the procedures specified in any protocol used in any such clinical trial or study, any claim of deviation, authorized or unauthorized, from the protocols of any such clinical trial or study, and any claim resulting from
or arising out of the manufacture or quality control by a third party of any substance administered in any clinical trial or study. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 9 

 8.3 The Indemnified Party shall promptly notify MYRIAD of any claim or action giving rise to Liabilities
subject to the provisions of the foregoing Section. MYRIAD shall have the right to defend any such claim or action, at its cost and expense. MYRIAD shall not settle or compromise any such claim or action in a manner that imposes any restrictions or
obligations on PENN or grants any rights to the JOINT PATENT RIGHTS or JOINT LICENSED PRODUCTS without PENN’s prior written consent. If MYRIAD fails or declines to assume the defense of any such claim or action within thirty (30) days
after notice thereof, PENN may assume the defense of such claim or action for the account and at the risk of MYRIAD, and any Liabilities related thereto shall be conclusively deemed a liability of MYRIAD. MYRIAD shall pay promptly to the Indemnified
Party any Liabilities to which the foregoing indemnity relates, as incurred. The indemnification rights of PENN or other Indemnified Party contained herein are in addition to all other rights which such Indemnified Party may have at law or in equity
or otherwise. 
 8.4 INSURANCE 
 8.4.1 MYRIAD shall procure and maintain a policy or policies of comprehensive general liability insurance, including broad form and contractual liability, in a minimum amount of [***] combined single limit per occurrence and in the
aggregate as respects personal injury, bodily injury and property damage arising out of MYRIAD’S performance of this AGREEMENT. 
 8.4.2
MYRIAD shall, upon commencement of clinical trials involving JOINT LICENSED PRODUCTS, procure and maintain a policy or policies of product liability insurance in a minimum amount of [***] combined single limit per occurrence and in the aggregate as
respects bodily injury and property damage arising out of MYRIAD’s performance of this AGREEMENT. 
 8.4.3 The policy or policies of
insurance specified herein shall be issued by an insurance carrier with an A.M. Best rating of “A” or better and shall name PENN as an additional insured with respect to MYRIAD’s performance of this AGREEMENT. MYRIAD shall provide
PENN with certificates evidencing the insurance coverage required herein and all subsequent renewals thereof. Such certificates shall provide that MYRIAD’s insurance carrier(s) notify PENN in writing at least [***] prior to cancellation or
material change in coverage. 
 8.4.4 PENN shall periodically review the adequacy of the minimum limits of liability specified herein.
Further, PENN reserves the right to request MYRIAD to adjust such coverage limits accordingly. The specified minimum insurance amounts shall not constitute a limitation on MYRIAD’s obligation to indemnify PENN under this AGREEMENT. 

 
 Portions of this Exhibit were omitted and have been filed separately with
the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 10 

 ARTICLE 9—USE OF PENN’S NAME; INDEPENDENT CONTRACTOR 
 9.1 MYRIAD and its employees and agents shall not use and MYRIAD shall not permit its sublicensees to use PENN’s name, any adaptation thereof, any
PENN logotype, trademark, service mark or slogan or the name mark or logotype of any PENN representative or organization in any way without the prior, written consent of PENN. 
 9.2 Nothing herein shall be deemed to establish a relationship of principal and agent between PENN and MYRIAD, nor any of their agents or employees for
any purpose whatsoever. This AGREEMENT shall not be construed as constituting PENN and MYRIAD as partners, or as creating any other form of legal association or arrangement which would impose liability upon one party for the act or failure to act of
the other party. 
 ARTICLE 10—ADDITIONAL PROVISIONS 
 10.1 MYRIAD shall comply with all prevailing laws, rules and regulations pertaining to the development, testing, manufacture, marketing, sale, use, import or export of products. Without limiting the foregoing, it is
understood that this AGREEMENT may be subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities, articles and information, including the Arms Export Control
Act as amended in the Export Administration Act of 1979, and that the parties obligations hereunder are contingent upon compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may
require a license from the cognizant agency of the United States Government and/or written assurances by MYRIAD that MYRIAD shall not export data or commodities to certain foreign countries without prior approval of such agency. PENN neither
represents that a license is not required nor that, if required, it will issue. 
 10.2 This AGREEMENT and the rights and duties appertaining
thereto may not be assigned by MYRIAD without first obtaining the express written consent of PENN. Any such purported assignment, without the written consent of PENN, shall be null and of no effect. 
 10.3 Notices, payments, statements, reports and other communications under this AGREEMENT shall be in writing and shall be deemed to have been received
as of the date dispatched if sent by public overnight courier (e.g. Federal Express) and addressed as follows: 
 If for PENN: 
 University of Pennsylvania 
 Center for
Technology Transfer 
 3700 Market Street, Suite 300 
 Philadelphia, PA 19104-3147 
 Attention: Managing Director 
 with a copy to: 
 Office of General Counsel

 University of Pennsylvania 
 211 College Hall 
 Philadelphia, PA 19104-6303 
 Attention: General Counsel 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended. 
  

 11 

 If for MYRIAD: 
 Myriad Genetics, Inc. 
 390 Wakara Way 
 Salt Lake City, UT 84108 
 Attention:
President 
 Either party may change its official address upon written notice to the other party. 
 10.4 This AGREEMENT shall be construed and governed in accordance with the laws of the Commonwealth of Pennsylvania, without giving effect to conflict of
law provisions. 
 10.5 This AGREEMENT and the MATERIAL TRANSFER. AGREEMENT are being entered into simultaneously and each is related to the
other in setting forth the entire agreement of the parties. Any modification of this AGREEMENT shall be in writing and signed by an authorized representative of each party. 
 10.6 In the event that a party to this AGREEMENT perceives the existence of a dispute with the other party concerning any right or duty provided for
herein, the parties shall, as soon as practicable, confer in an attempt to resolve the dispute. If the parties are unable to resolve such dispute amicably, then the parties hereby submit to the exclusive jurisdiction of and venue in the courts
located in the Eastern District of the Commonwealth of Pennsylvania with respect to any and all disputes concerning the subject of this AGREEMENT. 
 10.7 A waiver by either party of a breach or violation of any provision of this AGREEMENT will not constitute or be construed as a waiver of any subsequent breach or violation of that provision or as a waiver of any breach or violation of
any other provision of this AGREEMENT. 
 10.8 Any of the provisions of this AGREEMENT which are determined to be invalid or unenforceable in
any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof or affecting the validity or unenforceability of any of the
terms of this AGREEMENT in any other jurisdiction. 
 10.9 The headings and captions used in this AGREEMENT are for convenience of reference
only and shall not affect its construction or interpretation. 
 10.10 Nothing in this AGREEMENT, express or implied, is intended to confer
on any person, other than the parties hereto or their permitted assigns, any benefits, rights or remedies. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 12 

 10.11 PENN and MYRIAD shall not discriminate against any employee or applicant for employment because of
race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, or handicap. 
  
 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule
24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 13 

 IN WITNESS WHEREOF the parties, intending to be legally bound, have caused this AGREEMENT to be executed by their duly
authorized representatives. 
 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 
  

			
	SIGNATURE:	 	 /s/ Louis Berneman

		 	Louis Berneman
		 	Managing Director
		 	Center for Technology Transfer

			
		
	DATE:	 	3/13/96

			
	
	MYRIAD GENETICS, INC.
		
	SIGNATURE:	 	 /s/ Peter D. Meldrum

		 	Peter Meldrum
		 	President and CEO

			
		
	DATE:	 	3/13/96

  
 Portions of this
Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 14 

 Attachment 1 
  

					
	 	 	 Patent Number
	  	 Title

			
	1.	 	[***]	  	[***]
			
	2.	 	[***]	  	[***]
			
	3.	 	[***]	  	[***]

  
 Portions of this
Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
  

 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]